$65 million Series A financing in EyeBio

Independent private equity firm dedicated to biotech and biopharma Jeito Capital today announced that it has co-led a $65 million Series A financing round in EyeBiotech Limited (EyeBio), a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases.

The Series A brings together a team of international executives and investors with an extensive track record for developing ground-breaking ophthalmology therapies.

Jeito co-led the financing with SV Health Investors and Samsara BioCapital, with additional financial backing from MRL Ventures. Jeito Capital’s newly-appointed partner, Andreas Wallnoefer, will join EyeBio’s board of directors, Kate Bingham, managing partner at SV Health Investors, and Srinivas Akkaraju, founder and managing general Dr David Guyer, and Dr Anthony Adamis, working with collaborators at SV Health Investors, who provided seed funding and helped to recruit leadership and to initiate pipeline development.